Cellectis, Precision Bio Differ on EPO Decision Regarding Gene-Engineering Patent | GenomeWeb

NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said yesterday that that the European Patent Office has upheld one of its patents that has been the subject of ongoing litigation with US biotech firm Precision BioSciences.

However, in a statement released this morning, Precision BioSciences said that the EPO had "severely restricted" Cellectis' claims under the patent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.